RU2003102607A - Способы доставки лекарства в гепатоциты и лечение инфекций флавивирусов - Google Patents

Способы доставки лекарства в гепатоциты и лечение инфекций флавивирусов Download PDF

Info

Publication number
RU2003102607A
RU2003102607A RU2003102607/15A RU2003102607A RU2003102607A RU 2003102607 A RU2003102607 A RU 2003102607A RU 2003102607/15 A RU2003102607/15 A RU 2003102607/15A RU 2003102607 A RU2003102607 A RU 2003102607A RU 2003102607 A RU2003102607 A RU 2003102607A
Authority
RU
Russia
Prior art keywords
compound
hepatocyte
carrier
carboxamidine
group
Prior art date
Application number
RU2003102607/15A
Other languages
English (en)
Russian (ru)
Inventor
Джонсон ЛО (US)
Джонсон ЛО
Жи ХОНГ (US)
Жи ХОНГ
Original Assignee
Рибафарм Инк. (US)
Рибафарм Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рибафарм Инк. (US), Рибафарм Инк. filed Critical Рибафарм Инк. (US)
Publication of RU2003102607A publication Critical patent/RU2003102607A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
RU2003102607/15A 2000-08-22 2001-08-21 Способы доставки лекарства в гепатоциты и лечение инфекций флавивирусов RU2003102607A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22686900P 2000-08-22 2000-08-22
US60/226,869 2000-08-22
US24062700P 2000-10-13 2000-10-13
US60/240,627 2000-10-13

Publications (1)

Publication Number Publication Date
RU2003102607A true RU2003102607A (ru) 2004-07-27

Family

ID=26920944

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003102607/15A RU2003102607A (ru) 2000-08-22 2001-08-21 Способы доставки лекарства в гепатоциты и лечение инфекций флавивирусов

Country Status (15)

Country Link
EP (1) EP1313469A1 (cs)
JP (1) JP2004506684A (cs)
KR (1) KR20030040416A (cs)
CN (1) CN1447692A (cs)
AU (1) AU2001292557A1 (cs)
BR (1) BR0113388A (cs)
CA (1) CA2415793A1 (cs)
CZ (1) CZ2003308A3 (cs)
HU (1) HUP0302884A2 (cs)
IL (1) IL154167A0 (cs)
MX (1) MXPA03001529A (cs)
NO (1) NO20030794L (cs)
PL (1) PL365744A1 (cs)
RU (1) RU2003102607A (cs)
WO (1) WO2002015904A1 (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
US7608258B2 (en) 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2010042658A1 (en) 2008-10-07 2010-04-15 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5959077A (en) * 1993-05-26 1999-09-28 Laboratori Balducci S.P.A. Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR20030040416A (ko) 2003-05-22
EP1313469A1 (en) 2003-05-28
CA2415793A1 (en) 2002-02-28
PL365744A1 (en) 2005-01-10
MXPA03001529A (es) 2004-04-02
WO2002015904B1 (en) 2002-07-04
CN1447692A (zh) 2003-10-08
BR0113388A (pt) 2004-02-25
AU2001292557A1 (en) 2002-03-04
NO20030794L (no) 2003-04-22
NO20030794D0 (no) 2003-02-20
HUP0302884A2 (hu) 2003-12-29
CZ2003308A3 (cs) 2004-03-17
WO2002015904A1 (en) 2002-02-28
JP2004506684A (ja) 2004-03-04
IL154167A0 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
Bhatia et al. Sofosbuvir: A novel treatment option for chronic hepatitis C infection
Stuyver et al. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites
Cha et al. Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection
Pereira et al. New and experimental therapies for HCV
US20130109647A1 (en) Methods and compositions for treating hepatitis c virus
Sarin et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B
KR20110116136A (ko) Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체
HRP20020929A2 (en) Sustained release pharmaceutical cmpositions for parenteral administration of hydrophilic compounds
De Kanter et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations
Bourlière et al. How to optimize HCV therapy in genotype 1 patients with cirrhosis
WO2013066748A1 (en) Methods and compositions for treating hepatitis c virus
Serranti et al. New treatments for chronic hepatitis C: an overview for paediatricians
Rodríguez-Torres Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient
Mondelli The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
Paeshuyse et al. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors
WO2002015904B1 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
Bhopale et al. Emerging drugs for chronic hepatitis C
Walker et al. Beneficial effects of oral uridine in mitochondrial toxicity
Saleem et al. Current trends in the treatment of hepatitis C: interventions to avoid adverse effects and increase effectiveness of anti-HCV drugs
Ancel et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin
González-Moreno et al. Hepatitis C virus infection: looking for interferon free regimens
CN101489579B (zh) 病毒性疾病的预防或治疗剂
Rustgi Thymalfasin for the treatment of chronic hepatitis C infection
US20040077563A1 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
Verna et al. Hepatitis C treatment in patients on the liver transplant waiting list

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20050527